by The pruritus therapeutics market consists of drugs used for the treatment of itching or pruritus. Pruritus, commonly known as itching, is a distressing sensation that prompts the urge to scratch. It occurs as an acute or chronic symptom of many dermatologic, systemic, and psychiatric conditions. Various antihistamines, local anesthetics, corticosteroids, immunomodulators, and other drugs are used in the medical management of itching. The market is growing due to the rising prevalence of pruritic conditions such as atopic dermatitis, allergic contact dermatitis, urticaria, psoriasis, and others.
Pruritus therapeutics are essential for the management of itching associated with various skin conditions and systemic diseases. Antihistamines are first-line treatment options for acute or intermittent itch. Corticosteroids work effectively for inflammation-driven itch by reducing itch-sensitive opioid receptors and blocking immune cells. Immunomodulators like calcineurin inhibitors suppress T-cell mediated skin inflammation and itching caused by chronic conditions. Local anesthetics provide temporary relief from localized itching.
The global pruritus therapeutics market is estimated to be valued at US$ 81.38 Mn in 2024 and is expected to exhibit a CAGR of 6.9% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the pruritus therapeutics market are Levantina, Polycor, Indian Natural Stones, Topalidis, Dermitzakis, Antolini, Amso, Pakistan Onyx Marble & Granite, Etgran, Mumal Marbles, Tepia, Arizona Tile, Vetter Stone, Tekmarble & Granite, Temerty Stone, Dal Tile, M S International, Pokarna Limited, and Cosentino.
The growing prevalence of chronic diseases that cause pruritus like atopic dermatitis, chronic kidney disease, liver disease, and others is driving for effective Pruritus Therapeutics Market Size. According to the International Forum for the Study of Itch, over 20% of adults and up to 30% of children worldwide suffer from chronic itch at least once in their lifetimes.
Pharmaceutical companies are actively expanding their global footprint through collaborations and acquisitions to meet the international demand for anti-itch therapies. For instance, in 2021, Pfizer established a commercial agreement with Japanese firm Torii Pharmaceutical to sell anti-itch cream Eucrisa in more than 20 Asian markets.
Market key trends
Clinical research on novel targeted therapies holds promise for improving pruritus management. Biologics like interleukin antagonists, antibodies against pruriceptors, and neurokinin antagonists aim to interrupt specific pathways causing itch. Tachykinin receptor antagonists work by blocking tachykinin receptors involved in nerve signaling and sensory processing linked with chronic itch. Several candidates are under active investigation to offer disease modifying effects and relief from refractory itch conditions.
Porter’s Analysis
Threat of new entrants: The Pruritus Therapeutics market already has large and established players making market entry difficult for new players due to high capital requirement.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternative treatment options but demand for highly effective treatment options acts as a driver.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of substitutes but manufacturing complexity provides some bargaining power.
Threat of new substitutes: Threat of new substitutes is moderate as pruritus has few effective treatment options however research in potential new therapies can lead to new substitutes.
Competitive rivalry: Market is competitive with large players constantly striving to gain market share through product differentiation and innovations.
Geographical Regions
North America dominates the global Pruritus Therapeutics market owing to high healthcare expenditure and extensive research activities for novel therapies. The region accounts for nearly 40% of the global market value currently.
Asia Pacific is expected to grow at the fastest pace during the forecast period owing to increasing patient pool, rising awareness about treatment options and improving healthcare infrastructure. Majority of fast growing economies in Asia Pacific are expected to supplement this high growth rate through 2031.
Europe accounts for around 30% of the global Pruritus Therapeutics market value due to widespread medical insurance and easy adoption of advanced therapies. Support for research activities additionally aids Europe’s large market share.
RoW regions such as Latin America and Middle East & Africa contribute to around 15% of global market value currently but offer scope for high growth with expanding medical access and insurance coverage over the next decade. Developing nations will be major revenue generators in these regions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
